BioDelivery Sciences International, Inc. (BDSI) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 0.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 470,726 shares of the specialty pharmaceutical company’s stock after buying an additional 658 shares during the quarter. Geode Capital Management LLC owned approximately 0.86% of BioDelivery Sciences International worth $894,000 as of its most recent SEC filing.

Separately, Blair William & Co. IL boosted its position in BioDelivery Sciences International by 37.6% during the first quarter. Blair William & Co. IL now owns 693,181 shares of the specialty pharmaceutical company’s stock worth $1,386,000 after purchasing an additional 189,484 shares in the last quarter. Institutional investors own 41.44% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BioDelivery Sciences International, Inc. (BDSI) Shares Bought by Geode Capital Management LLC” was posted by BBNS and is the property of of BBNS. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/biodelivery-sciences-international-inc-bdsi-shares-bought-by-geode-capital-management-llc/1603804.html.

A number of analysts have issued reports on the company. Janney Montgomery Scott lifted their price target on BioDelivery Sciences International from $3.00 to $4.00 and gave the stock a “fair value” rating in a report on Monday, July 24th. Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday, July 17th. HC Wainwright started coverage on BioDelivery Sciences International in a research report on Friday, May 26th. They set a “buy” rating and a $4.00 target price on the stock. ValuEngine cut BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of BioDelivery Sciences International in a research report on Sunday, August 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $4.21.

BioDelivery Sciences International, Inc. (BDSI) traded down 1.69% during trading on Friday, reaching $2.90. The company’s stock had a trading volume of 228,076 shares. The stock has a market capitalization of $160.88 million, a price-to-earnings ratio of 103.57 and a beta of 1.04. The firm has a 50 day moving average of $3.14 and a 200 day moving average of $2.45. BioDelivery Sciences International, Inc. has a 52 week low of $1.50 and a 52 week high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.45 million. During the same quarter last year, the firm posted ($0.31) earnings per share. BioDelivery Sciences International’s revenue was up 74.0% on a year-over-year basis. Analysts expect that BioDelivery Sciences International, Inc. will post $0.12 EPS for the current year.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw


Leave a Reply

 
© 2006-2017 BBNS.